Watson Pharma sues FDA over generic Actos ruling
Watson Pharmaceuticals believes it is entitled to shared marketing exclusivity on generic Actos.
Watson Pharmaceuticals has announced that it is suing the US Food and Drug Administration (FDA) over a ruling that could delay approval of the company's generic version of the diabetes drug Actos by up to six months.
The company says that the FDA has "improperly" denied its shared exclusivity for its generic version of Actos, despite the company following directions received from the FDA.
It believes it should be allowed to launch its generic drug on August 17th 2012 as planned, enjoying shared market exclusivity for 180 days with Mylan and Ranbaxy.
Paul Bisaro, president and chief executive officer at Watson, revealed that the company had tried to work "cooperatively" with the FDA when it learned of the agency's views on its application.
"FDA has refused to grant shared exclusivity and seeks to unnecessarily delay the launch of Watson's generic Actos product, with potential harm to consumers
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
.png)
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.